Overview

CR-CHOP+X in Previously Untreated DEL

Status:
RECRUITING
Trial end date:
2028-12-01
Target enrollment:
Participant gender:
Summary
This is a prospective, single-arm, open-label phase II clinical trial that evaluates the efficacy and safety of CR-CHOP regimen combined with different targeted drugs based on different molecular subtypes in newly diagnosed DEL patients.
Phase:
PHASE2
Details
Lead Sponsor:
Ruijin Hospital
Treatments:
Decitabine
orelabrutinib